MedTrace Logo

Efficacy of Platelet-rich Plasma in Treatment of Melasma

NCT03674203 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2019-01-28

No results posted yet for this study

Summary

The application of Platelet Rich Plasma (PRP) on three occasions with an interval of 15 days between each one, is related to a decrease in the intensity of the spots and improvement in the quality of the skin of patients with melasma.

Conditions

  • Melasma

Interventions

BIOLOGICAL

Platelet-Rich Plasma

1 ml of PRP was distributed in the papillary dermis of the face, repeating the dose at 15 and 30 days.

Sponsors & Collaborators

  • Instituto Mexicano del Seguro Social

    lead OTHER_GOV

Principal Investigators

  • Clotilde Fuentes, pHD · Instituto Mexicano del Seguro Social

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2018-05-31
Completion
2018-07-31

Countries

  • Mexico

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03674203 on ClinicalTrials.gov